Korro Bio plans a reverse merger with Frequency Therapeutics to fund clinical studies of its lead candidate, designed to treat alpha-1 antitrypsin deficiency (AATD) in the liver.
Frequency Change: Korro Bio Edits Its Message, Rewrites Its Future with Reverse Merger
Posted in biotech/medical, futurism